Department of Surgery, Fukuoka City Hospital, 13-1 Yoshizuka-honmachi, Hakata-ku, Fukuoka, 812-0046, Japan.
Surg Today. 2012 Aug;42(8):734-40. doi: 10.1007/s00595-012-0129-5. Epub 2012 Jan 27.
We conducted this retrospective study to evaluate the effectiveness of giving oral anti-cancer drugs for 2 years as postoperative adjuvant chemotherapy to gastric cancer patients.
The subjects were 76 patients with stage II and III gastric cancer, who underwent curative surgery between 1989 and 2008. We divided the 20 years chronologically into the UFT term (1989-2003) and the S-1 term (2004-2008). The patients from each term were then divided into three groups according to the length of drug administration; namely, the surgery alone group, the 1-year group, and the 2-year group.
The survival time of the 2-year group was better than that of the surgery alone group, not only in the UFT term, but also in the S-1 term (P = 0.0224). Longer relapse-free survival was evident in the S-1 term, especially for the 2-year group (P = 0.0110). A multivariate analysis showed both the stage of the cancer and 2 years of postoperative adjuvant chemotherapy to be independent factors predictive of prolonged survival (P = 0.0040 and P = 0.0022, respectively).
The 2-year administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy might improve the outcome of stage II, III gastric cancer patients. Randomized control trials are warranted to prove the effectiveness of this 2-year regimen.
本研究回顾性评估了给予胃癌患者口服抗癌药物 2 年作为术后辅助化疗的疗效。
本研究对象为 1989 年至 2008 年间接受根治性手术的 76 例 II 期和 III 期胃癌患者。我们将这 20 年分为 UFT 期（1989-2003 年）和 S-1 期（2004-2008 年）。然后根据药物治疗时间的长短，将每个时期的患者分为三组：单纯手术组、1 年组和 2 年组。
2 年组的生存时间优于单纯手术组，不仅在 UFT 期，而且在 S-1 期也是如此（P=0.0224）。S-1 期无复发生存时间更长，特别是 2 年组（P=0.0110）。多因素分析显示，癌症分期和术后辅助化疗 2 年是延长生存的独立因素（P=0.0040 和 P=0.0022）。
口服抗癌药物 2 年作为术后辅助化疗可能改善 II 期、III 期胃癌患者的预后。需要进行随机对照试验来证明这种 2 年方案的有效性。
